Genmab — April 2020

[E_L]

Van de Winkel adds: ‘Our scientists will also use their knowledge to help with the response to coronavirus disease, to add our expertise and our insights to create an effective therapeutic candidate much more rapidly https://investinholland.com/success-stories/genmab/?utm_campaign=coschedule&utm_source=twitter&utm_medium=nfiaholland&utm_content=Genmab

[Plimsoller]

Good. We need smart people to help these days.

[E_L]

ADCT-301 Ph II seems fully accrued https://clinicaltrials.gov/ct2/history/NCT04052997?A=15&B=16&C=merged#StudyPageTop

[gdn55]

Kan ugen godkendes? Jeg er meget tilfreds, frygtede det værste.

[JKY_VH]

Den er absolut godkendt og god weekend:-)

[Solsen]

Tilfredshed herfra og god weekend

[gentogen]

EL 15.47: I am not so sure. That would be extremely quick. They are including new location in new countries in the trial so perhaps it is just for the time being they are not recruiting?

[E_L]

yes, that is certainly also possible,... i was actually happy that they finished so quick and just in time before corona shut recruitment down, but maybe exactly that happened...

[E_L]

New BMS-986253 trial: Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04347226

[Solsen]

Thanks EL you are a master

[E_L]

haha, fortunately there are enough here to correct all my mistakes

[Solsen]

Well we dont know about ADC-301. You could be right...

[Solsen]

Vi mangler lidt over 3% for at NBI er i ATH

[GeorgeBest]

I 2015 var vi vist højere på NBI...

[Bulder]

Stærkt us-luk. Ikke mindst trukket op af remdesivir-rygterne. Så må vi se om de holder.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Solsen]

Korrekt GB https://finance.yahoo.com/quote/^NBI?p=^NBI

[StockBull]

Remdesivir: science remains equivocal about whether this drug actually works for covid-19 sufferers. Two trials in China have already failed, because of lack of enrolment. (China started its trials relatively late in its epidemic, so it was hard to recruit sufficient numbers of patients.) The recent publication in the New England Journal of Medicine, of a study of remdesivir given to 53 severely afflicted patients, reported that 68% of them improved.

[StockBull]

However the study has proven divisive among scientists. To begin with, errors can be large given the small number of patients. Moreover, the trial was not “randomised”, so there is no way of knowing whether the sample properly reflects the population of severely afflicted patients. Last, there was no comparison group that was given a placebo, ie, a substance with no therapeutic effect, to establish the real effectiveness of the drug.